Tennis' world No 1 Novak Djokovic reportedly holds an 80% stake in a biotech company aiming to develop a treatment for Covid, which does not involve vaccination.
Djokovic has long been opposed to the Covid vaccine, and now appears invested in finding a way he can protect himself and others who are opposed to having their jab.
Reuters have reported the Serb - who was recently deported from Australia after having his visa revoked twice having initially been granted a medical exemption - has joined forces with Danish biotech firm QuantBioRes.
The biotech firm's chief executive Ivan Loncarevic revealed that the investment was made by the Serbian back in June 2020, but declined to disclose the exact fee.
QuantBioRes employs 11 researchers who have been working out of Denmark, Australia and Slovenia to find a treatment against the virus.
The company is reportedly developing a peptide, which prevents Covid from infecting the human cell.
The Danish company is expecting to launch clinical trials in Britain as early as this summer.
But the timings could put paid to his hopes of competing in the remaining three Grand Slams after missing out on the Australian Open.
It comes as no surprise that Djokovic is keen to find a treatment for Covid given he is opposed to taking the vaccines available to fight the virus.
Ultimately the 34-year-old's decision to remain unvaccinated denied him the opportunity to defend his title at the Australian Open.
The world No 1 was deported from Australia, partly due to not being vaccinated, following a second court ruling and faces a ban from the sport's other Grand Slams.
The French Open declared he needs to be vaccinated to participate, as well as the US Open.
Wimbledon meanwhile, provided no guarantees that Djokovic will be able to grace Centre Court this summer without being inoculated.
